NCT01810120View on ClinicalTrials.gov

Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Acute Lymphoblastic LeukemiaLeukemia Acute Myeloid - AMLNon-Hodgkin LymphomaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

TCR alfa beta T cell depletion

total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient

Trial Locations (1)

00165

Department of Oncology/Hematology of the Hospital Bambino Gesù (Roma), Rome

All Listed Sponsors
lead

Mariella Enoc

OTHER

NCT01810120 - Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | Biotech Hunter | Biotech Hunter